LP
ALT icon

LMR Partners’s Altimmune ALT Stock Holding History

LMR Partners’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250,000
Closed -$903K – 1438
2025
Q4 		$903K Hold
250,000
– – ﹤0.01% 1011
2025
Q3 		$943K Sell
250,000
-102,800
-29% -$397K ﹤0.01% 951
2025
Q2 		$1.37M Buy
+352,800
New +$1.91M 0.01% 726

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LMR Partners's ALT Position: Q2 2026 in Review

LMR Partners opened a new position in Altimmune (ALT) in Q2 2026: 300,000 shares worth $912K. The stake represents ﹤0.01% of the portfolio and ranks #1070 among its holdings. This is a return to the name: LMR Partners previously reported a position in ALT as recently as Q4 2025.

LMR Partners first reported a position in ALT in Q2 2017 and has held it in 11 quarters since. 211 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • LMR Partners held 300,000 shares of Altimmune worth $912K as of Q2 2026.
  • Altimmune was a new LMR Partners position in Q2 2026.
  • Altimmune made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1070 holding.
  • LMR Partners first reported a position in Altimmune in Q2 2017 and has held it in 11 quarters since.
  • 211 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.